{"title":"Experience With Adaptive Servo-Ventilation Among Veterans in the Post-SERVE-HF Era.","authors":"Phillip A Nye, Sean E Hesselbacher","doi":"10.12788/fp.0374","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The sleep medicine community has struggled to identify the ideal role for adaptive servo-ventilation (ASV) therapy following a study that found increased mortality in patients with central sleep apnea (CSA) and heart failure with reduced ejection fraction who used ASV therapy. We aimed to identify characteristics of patients who benefit from ASV therapy.</p><p><strong>Methods: </strong>We performed a record review of all patients treated with ASV therapy at the Hampton Veterans Affairs Medical Center in Virginia from January 1, 2015, to April 30, 2020. Clinical and polysomnographic characteristics of patients adherent to therapy were compared with those that were not adherent.</p><p><strong>Results: </strong>Our cohort of 31 patients was entirely male with a mean age of 67.2 years, body mass index of 34.0, and Epworth Sleepiness Scale score of 10.9. Primary CSA was initially diagnosed in 3 patients (10%), comorbid obstructive sleep apnea (OSA) and CSA in 9 (29%), and primary OSA in 19 (61%). Seventeen patients (55%) met minimal adherence criteria with ASV therapy. The obstructive apnea-hypopnea index (AHI), as a proportion of the total pretreatment AHI, was higher in adherent patients (81.5%) vs nonadherent patients (46.7%) (<i>P</i> = .02). The median residual AHI was lower in the adherent group, both as absolute values (1.7 vs 4.7 events/h; <i>P</i> = .004) and as a percentage of the pretreatment AHI (3.1% vs 10.2%; <i>P</i> = .002).</p><p><strong>Conclusions: </strong>Patients using ASV devices regularly have a larger component of obstructive sleep-disordered breathing and obtain greater objective benefit from ASV than those that do not. This understanding may help to identify patients that will most benefit from this debated form of therapy.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 5","pages":"152-159a"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506493/pdf/fp-40-05-152.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/fp.0374","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The sleep medicine community has struggled to identify the ideal role for adaptive servo-ventilation (ASV) therapy following a study that found increased mortality in patients with central sleep apnea (CSA) and heart failure with reduced ejection fraction who used ASV therapy. We aimed to identify characteristics of patients who benefit from ASV therapy.
Methods: We performed a record review of all patients treated with ASV therapy at the Hampton Veterans Affairs Medical Center in Virginia from January 1, 2015, to April 30, 2020. Clinical and polysomnographic characteristics of patients adherent to therapy were compared with those that were not adherent.
Results: Our cohort of 31 patients was entirely male with a mean age of 67.2 years, body mass index of 34.0, and Epworth Sleepiness Scale score of 10.9. Primary CSA was initially diagnosed in 3 patients (10%), comorbid obstructive sleep apnea (OSA) and CSA in 9 (29%), and primary OSA in 19 (61%). Seventeen patients (55%) met minimal adherence criteria with ASV therapy. The obstructive apnea-hypopnea index (AHI), as a proportion of the total pretreatment AHI, was higher in adherent patients (81.5%) vs nonadherent patients (46.7%) (P = .02). The median residual AHI was lower in the adherent group, both as absolute values (1.7 vs 4.7 events/h; P = .004) and as a percentage of the pretreatment AHI (3.1% vs 10.2%; P = .002).
Conclusions: Patients using ASV devices regularly have a larger component of obstructive sleep-disordered breathing and obtain greater objective benefit from ASV than those that do not. This understanding may help to identify patients that will most benefit from this debated form of therapy.
背景:睡眠医学界一直在努力确定自适应伺服通气(ASV)治疗的理想作用,此前一项研究发现,使用ASV治疗的中枢性睡眠呼吸暂停(CSA)和射血分数降低的心力衰竭患者死亡率增加。我们旨在确定受益于ASV治疗的患者的特征。方法:我们对2015年1月1日至2020年4月30日在弗吉尼亚州汉普顿退伍军人事务医疗中心接受ASV治疗的所有患者进行了记录回顾。将坚持治疗的患者与不坚持治疗的病人的临床和多导睡眠图特征进行比较。结果:我们的31名患者均为男性,平均年龄67.2岁,体重指数34.0,Epworth嗜睡量表评分10.9。原发性CSA最初诊断为3例(10%),合并阻塞性睡眠呼吸暂停(OSA)和CSA的患者9例(29%),原发性OSA的患者19例(61%)。17名患者(55%)符合ASV治疗的最低依从性标准。粘连患者的阻塞性呼吸暂停低通气指数(AHI)占治疗前总AHI的比例(81.5%)高于非粘连患者(46.7%)(P=0.02),无论是作为绝对值(1.7 vs 4.7事件/h;P=0.004)还是作为预处理AHI的百分比(3.1%vs 10.2%;P=0.002)。这种理解可能有助于确定从这种有争议的治疗形式中受益最多的患者。